Navigation Links
Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
Date:6/16/2008

who have been diagnosed with RA more than six months prior to the study with onset of RA after the age of 16.

"We believe SBI-087 and TRU-015 together will play an important role in improving patient care and helping us establish category leadership in autoimmune and inflammatory disease markets," said Peter Thompson, M.D., FACP, president, CEO and chairman of Trubion. "With more than 100 re-treatment courses of TRU-015 now administered, these data further demonstrate TRU-015's ability to maintain consistent and predictable RA response rates following re-treatment with a single dose given every six months. We look forward to the results of Wyeth's ongoing TRU-015 Phase 2b study designed to identify a preferred induction, or initial, dosing regimen. The results from this study, combined with our re-treatment experience to date, will allow us to further establish TRU-015's competitive profile for patients with RA."

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional a
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
2. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
6. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
7. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
8. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
9. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
10. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
11. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... advance from Hercules Technology Growth Capital, Inc. (NYSE: ... and final advance under the Loan and Security Agreement ... , Alimera Sciences Limited, entered into with Hercules ...
(Date:9/30/2014)... -- A study using a relatively new imaging tool, ... the composition of carotid artery disease and has the ... disease, a leading cause of stroke. ... 2010 and May 2012, was featured in the June ... College of Cardiology (JACC) Cardiovascular Interventions. Interventional cardiologist ...
(Date:9/30/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... Bridgewater, New Jersey location received ... Administration (FDA) relating to an inspection in June 2014 ... injectable, which was divested to Galderma S.A. in July ... contract manufacturers (rather than Valeant,s own internal manufacturing) with ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... conducted by Dobson | DaVanzo & Associates found that ... (DME) may limit Medicare beneficiaries, access to home medical ... products that Medicare consumers rely on.   ... Americans who require oxygen equipment and therapy, mobility assistive ...
... Sept. 14, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: ... LLY ) and Alkermes, Inc. (Nasdaq: ... on BYETTA® (exenatide) injection and the investigational product BYDUREON™ ... the 46th Annual Meeting of the European Association for ...
Cached Medicine Technology:Independent Study Concludes Medicare 'Competitive' Bidding Program for Durable Medical Equipment Could Negatively Affect Care Access, Quality, and Choice for Seniors and People with Disabilities 2Independent Study Concludes Medicare 'Competitive' Bidding Program for Durable Medical Equipment Could Negatively Affect Care Access, Quality, and Choice for Seniors and People with Disabilities 3Independent Study Concludes Medicare 'Competitive' Bidding Program for Durable Medical Equipment Could Negatively Affect Care Access, Quality, and Choice for Seniors and People with Disabilities 4BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 2BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 3BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 4BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 5BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 6BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 7
(Date:10/1/2014)... modelling of the human eye, the brain of a ... and new technology, says a QUT leading robotics researcher. ... Engineering Faculty says the new study uses new computer ... high-density buildings or tunnels. , "This is a very ... putting two halves of a thing together because we,re ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 First Warning ... abnormal circadian cellular changes throughout the body, announced the ... to better address the company’s breadth of upcoming product ... breast cancer screening technology. , “Our initial focus will ... system which detects abnormal circadian cellular changes over time,” ...
(Date:10/1/2014)... new genetic finding from Duke Medicine suggests that some ... might also be hard-wired to gain weight when exposed ... , An estimated 13 percent of people, all of ... knowing this could help them reduce heart disease with ... stress management. , "Genetic susceptibility, psychosocial stress and metabolic ...
(Date:10/1/2014)... NoteSwift Inc., announced today their new NoteSwift™ 2.0 for ... is the bridge between the EHR and Dragon Medical ... information at the point of care. NoteSwift reduces the ... more than half – and virtually eliminates mouse clicks ... impedes EHR use according to the June 12, 2014 ...
Breaking Medicine News(10 mins):Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3
... said that it will announce a new brand of coffee ... 21 years of research, the CCRI expects to release the ... arabica variety is resistant to diseases such as leaf rust ... borer. ,CCRI officials said trials of the new ...
... again when she was pictured with baby bump . ... Travolta starrer Hairspray dressed in a figure-hugging black dress that ... ,Holmes sparked off rumours that she and hubby ... spotted with bump while visiting new best friends David and ...
... been ruled out of the entire Test series against India ... be out for four to six weeks, reports BBC . ... the hernia has come back and now it's all about ... Anderson, Stuart Broad and Chris Tremlett are vying for the ...
... Wednesday said the government was not averse to inviting the ... a mosquito borne fever in the state that has claimed ... expert teams have arrived in the state since the outbreak ... which have confirmed the fever as chikunguniya and nothing else, ...
... can overcome their problem by taking part in group ... ,The study also suggests that supplementing sildenafil, sold ... names, to group therapy can make the treatment more ... function relies on the coordination of psychological, endocrine, vascular, ...
... has reserved seats for students suffering from AIDS and cancer ... has reserved one seat for each of the fifty-six courses ... from cancer. ,However, the university feels that one ... time being, since it do not expects many patients queuing ...
Cached Medicine News:Health News:Harmison Ruled Out Off Test Series Due to Hernia 2
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Irrigating nucleus chopper, wedge-shaped inferior edge with, blunt tip, 0.6 mm dual sideports, 20 gauge....
Nucleus chopper. For bimanual nucleus division....
Medicine Products: